Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2954 • 2015 ACR/ARHP Annual Meeting
Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Maria Boge Lauvsnes¹, Anne Bolette Tjensvoll², Ingeborg Kvivik³, Roald Omdal⁴ and Chaim Putterman⁵, ¹Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ³Reasearch Department, Stavanger University Hospital, Stavanger, Norway, ⁴Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁵Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric manifestations are commonly observed in both SLE and primary Sjšgren's syndrome (pSS). However, making an accurate diagnosis can be challenging. Multiple serum and…
Abstract Number: 625 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Frederick B Vivino¹, Steven E. Carsons², Ann Parke³, Nancy Carteron⁴, Vidya Sankar⁵, Richard Brasington⁶, Robert Fox⁷, William Ehlers³, Michael Brennan⁸, Robert Hal Scofield⁹, Katherine M Hammitt¹⁰ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ³University of Connecticut, Farmington, CT, ⁴University of California, San Francisco, CA, ⁵Univeristy of Texas, San Antonio, TX, ⁶Washington University, St Louis, MO, ⁷Rheumatology Clinic, La Jolla, CA, ⁸Carolinas Medical Center, Charlotte, NC, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁰Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS). Clinical practice guidelines were developed for…
Abstract Number: 647 • 2015 ACR/ARHP Annual Meeting
Involvement of Peripheral Nervous System in Primary Sjögren Syndrome, a Gessar Analysis
M. Mayer¹, S. Velez², F. Zazzetti², J. C. Barreira², L. Galvan¹, G. Bennasar³, L. R. Carlevaris³, A. Secco³, C. Asnal⁴, P. Pucci⁴, C. Amitrano⁴, A. Nitsche⁴, M. C. Khoury⁵, F. Caeiro⁶, N. Benzaquén⁶, J.P. Pirola⁶, M. Colazo⁶, O.L. Rillo⁷, S. Papasidero⁷, J. Demarchi⁷, L. Raitti⁸, M. N. Tamborenea⁹, M. L. Santiago⁹, P. Alba¹⁰, B. Busamia¹⁰, G. Salvatierra¹¹ and A. Catalán Pellet³, ¹Rheumatology, Buenos Aires British Hospital, CABA, Argentina, ²Rheumatology, Buenos Aires British Hospital, Buenos Aires, Argentina, ³Rivadavia Hospital, CABA, Argentina, ⁴German Hospital, CABA, Argentina, ⁵Statistics, Buenos Aires British Hospital, CABA, Argentina, ⁶Private Hospital of Cordoba, Cordoba, Argentina, ⁷Tornú Hospital, CABA, Argentina, ⁸Bessone Clinic, CABA, Argentina, ⁹OMI, Buenos Aires, CABA, Argentina, ¹⁰Córdoba Hospital, Cordoba, Argentina, ¹¹IPRI, Santiago del Estero, Santiago del Estero, Argentina
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by dysfunction of the exocrine glands. The frequency of neurological manifestations in pSS ranges from…
Abstract Number: 2282 • 2015 ACR/ARHP Annual Meeting
“Doing Every-Day Life” with Primary Sjögren’s Syndrome: Factors Predicting Difficulties Performing Daily Activities and Taking on Life Roles
Katie Hackett¹, Dennis W Lendrem², Tim Rapley³, Katherine Deane⁴, Vincent Deary⁵, Simon Bowman⁶, Julia Newton⁷, Wan-Fai Ng⁸ and on behalf of the United Kingdom Primary Sjogren's Syndrome Registry, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of East Anglia, Norwich, United Kingdom, ⁵School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁶Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is an autoimmune disease which targets secretory glands and results in dryness. In addition pSS patients frequently experience symptoms of…
Abstract Number: 3200 • 2015 ACR/ARHP Annual Meeting
Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model
Astrid Rasmussen¹, Christopher J Lessard², Indra Adrianto¹, Graham B. Wiley¹, Donald U Stone^3,4, C. Erick Kaufman⁵, Lida Radfar⁶, David M. Lewis⁷, Stephen K Young⁸, Michael H. Weisman⁹, Daniel J Wallace¹⁰, Swamy Venuturupalli¹¹, Barbara M. Segal¹², John A. Ice¹, Juan-Manuel Anaya¹³, Michael D. Rohrer¹⁴, Raj Gopalakrishnan¹⁵, Glen D Houston¹⁶, James Chodosh¹⁷, Pamela J Hughes¹⁸, Nelson L. Rhodus¹⁹, Jennifer A. Kelly²⁰, Kiely Grundahl²¹, Kimberly Hefner²², R. Hal Scofield^1,23,24 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁴Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, ⁵College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁷College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹³Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁴Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁵Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹⁶Heartland Pathology, Oklahoma City, OK, ¹⁷Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹⁸Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ²²Hefner Eye Care and Optical Center, Oklahoma City, OK, ²³Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Autoimmune diseases are often preceded by subclinical serologic and functional abnormalities that predate diagnosis by several years. The insidious and progressive nature of these…
Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Luca Quartuccio¹, Sara Salvin², Laura Corazza¹, Saviana Gandolfo², Martina Fabris³ and Salvatore De Vita⁴, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Rheumatology Clinic, University of Udine, Udine, Italy, ³Clinic of Rheumatology, University of Udine, Udine, Italy, ⁴Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…
Abstract Number: 648 • 2015 ACR/ARHP Annual Meeting
Klinefelter’s Syndrome (47,XXY) Among Men with Sjögren’s Syndrome
Valerie M Harris¹, Joshua Cavett², Biji Kurien³, Ke Liu⁴, Kristi A. Koelsch⁵, Lida Radfar⁶, David M. Lewis⁷, Donald U. Stone⁸, Shibo Li⁹, Barbara Segal¹⁰, Daniel J Wallace¹¹, Michael H. Weisman¹², Jennifer A. Kelly¹³, Marta Alarcon-Riquelme¹⁴, Bernado Pons-Estel¹⁵, Roland Jonsson¹⁶, Xianglan Lu⁹, Jacques Gottenberg¹⁷, Juan-Manuel Anaya¹⁸, Deborah S. Cunninghame-Graham¹⁹, Edward C. Keystone²⁰, Andrew J.W. Huang²¹, Michael T. Brennan²², Pamela Hughes²³, G Illei²⁴, Corinne Miceli²⁵, VP Bykerk²⁶, Gideon Hirschfield²⁷, Gang Xie²⁸, Wan-Fai Ng²⁹, Gunnel Nordmark³⁰, Per Eriksson³¹, Roald Omdal³², Nelson L. Rhodus³³, Maureen Rischmueller³⁴, Michael D. Rohrer³⁵, Marie Wahren-Herlenius³⁶, Torsten Witte³⁷, Xavier Mariette³⁸, Christopher Lessard³⁹, John B. Harley⁴⁰, Kathy L. Sivils³⁹ and Robert Hal Scofield⁴¹, ¹Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴3333 Burnet Ave., University of Cincinnati & Cincinnati Childre, Cincinnati, OH, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁷College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁹Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Rheumatology, Univ of Minnesota, Minneapolis, MN, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹³Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Arthritis & Clinical Immunology, Oklahoma Medical REsearch Foundtion, Oklahoma City, OK, ¹⁵Hospital Provincial de Rosario, Rosario, Argentina, ¹⁶Broegelmann research laboratory, Bergen, Norway, ¹⁷Hautepierre, Strasbourg, France, ¹⁸Cell Biol and Immunogenetics, CIB-Rosario University, Medellin, Colombia, ¹⁹Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ²⁰Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²¹Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, ²²Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ²³Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁴Sjögren's Clinic, NIDCR/NIH, Bethesda, MD, ²⁵Rheumatology, PARIS, France, ²⁶University of Toronto, Toronto, ON, Canada, ²⁷Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²⁸Mount Sinai Hospital, Toronto, ON, Canada, ²⁹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁰Medical Sciences, Uppsala University, Uppsala, Sweden, ³¹University Hospital, Rheumatology clinic, Linköping, Sweden, ³²Department of internal medicine, Clinical Immunology unit, Stavanger, Norway, ³³Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁴Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ³⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁶Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, ³⁷Department of Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³⁸Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴¹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Primary Sjögren’s syndrome (pSS) has a strong female bias of greater than 10 to 1. This difference in risk of disease between the sexes…
Abstract Number: 2516 • 2015 ACR/ARHP Annual Meeting
Association Between Primary Sjögren’s Syndrome and Pregnancy Outcome: A Systematic Review and Meta-Analysis
Sikarin Upala¹ and Anawin Sanguankeo², ¹Internal Medicine, Bassett Medical Center, Cooperstown, NY, ²Bassett Medical Center, Cooperstown, NY
Background/Purpose: Systemic autoimmune disorders may interfere with normal reproductive function resulting in negative outcome of pregnancy. Primary Sjögren's syndrome (pSS) is a common rheumatic disease…
Abstract Number: 3201 • 2015 ACR/ARHP Annual Meeting
IL-7 Drives Cytokine Secretion of IL-7Rabright CCR9-Expressing T-Follicular Helper-like Cells: Potential New Axis in Lymphoid Neogenesis in Salivary Glands of Primary Sjogren s Syndrome Patients
S.L.M. Blokland^1,2, M.R. Hillen^1,2, A.A. Kruize¹, A. Kislat³, S. Meller³, B. Homey³, G.M. Smithson⁴, J. Zalevsky⁵, T.R.D.J. Radstake^1,2 and J.A.G. van Roon^1,6, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Dermatology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany, ⁴Takeda Pharmaceuticals International, Chicago, IL, ⁵Takeda California, San Diego, CA, ⁶Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: In primary Sjögren’s syndrome (pSS) B cell hyperactivity including autoantibody secretion and lymphoma development are hallmark immunopathological features. Specific lymphoid organization (including germinal centers)…
Abstract Number: 627 • 2015 ACR/ARHP Annual Meeting
Clinical Subsets and Presenting Features in Primary Sjögren’s Syndrome: Results from a Single Center Inception Cohort Study
Chiara Baldini¹, Francesco Ferro¹, Nicoletta Luciano¹, Rosaria Talarico¹, Leonardo Lorenzini¹, Daniela Martini¹, Marta Mosca² and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²University of Pisa, Pisa, Italy
Background/Purpose: Aim of the study was to characterize the spectrum of presenting clinical features in a single-centre inception cohort of patients with primary Sjögren’s syndrome…
Abstract Number: 1051 • 2015 ACR/ARHP Annual Meeting
Serum Calprotectin As Biomarker of Carotid Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Gabriela Moreira Balarini¹, Eliana Zandonade², leandro tanure³, gilda Aparecida ferreira³, Wildner Mardegan Sardenberg⁴, Érica Vieira Serrano⁴, Cléia Coelho Dias⁵, Túlio Pinho Navarro³, João Felipe Tonini⁴, Hilde H Nordal⁶, Piotr Mydel⁷, Johan Gorgas Brun⁸, Karl Albert Brokstad⁹, Eva Gerdts⁸, Roland Jonsson^10,11 and Valeria Valim^4,12, ¹Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., cachoeiro de itapemirim, Brazil, ²Department of Statistic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, ³Department of Locomotor System, Federal University of Minas Gerais, Brazil., belo horizonte, Brazil, ⁴Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, ⁵Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vila velha, Brazil, ⁶Broegelmann Research Laboratory/University of Bergen, Norway, bergen, Norway, ⁷Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ⁸Department of Clinical Science, University of Bergen, Norway, bergen, Norway, ⁹Department of Clinical Science, University of Bergen, Norway., bergen, Norway, ¹⁰Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹¹Broegelmann research laboratory, Bergen, Norway, ¹²Rheumatology, Universidade Federal do Espírito Santo, Vitória, Brazil
Background/Purpose: The relationship between atherosclerosis, traditional risk factors, disease activity and biomarkers is not well explored. We aimed to identify the association of carotid atherosclerosis…
Abstract Number: 2517 • 2015 ACR/ARHP Annual Meeting
Primary Sjögren’s Syndrome and Pregnancy: Evolution of Thyroid Function, Xerostomia, Xerophthalmia and Salivary Test for Dental Caries Risk
Elisa Trujillo¹, Maria del Mar Trujillo², Erica Padron³, Maria Garcia-Gonzalez⁴, Lorena Exposito⁵, Hiurma Sanchez⁵ and Sandra Garcia⁶, ¹Hospital Universitario de Canarias, Servicio de Reumatologia, Tenerife, Spain, ²Servicio Canario de Salud., Servicio de Evaluación de tecnología Sanitaria, santa cruz de Tenerife, Spain, ³Hospital Universitario de Canarias, Servicio de Ginecología y Obstetricia., santa cruz de Tenerife, Spain, ⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Hospital Universitario de Canarias, Servicio de Reumatologia, santa cruz de Tenerife, Spain, ⁶Bow lane dental Group, Dentist, London, England
Background/Purpose: 1. To study the effect of pregnancy in PSS patients on oral and ocular dryness and the salivary test for dental caries activity. 2.…
Abstract Number: 3202 • 2015 ACR/ARHP Annual Meeting
Functional Anti-Muscarinic Receptor-3 Monoclonal Antibodies Derived from Salivary Gland in Patients of Sjögren’s Syndrome
Syed M.S. Quadri^1,2, Kristi A. Koelsch³, Valerie Harris⁴, Biji T Kurien⁵ and R. Hal Scofield⁶, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune inflammatory disease characterized by bilateral hypofunction of lacrimal and salivary glands leading to keratoconjuctivitis and xerostomia. The…
Abstract Number: 628 • 2015 ACR/ARHP Annual Meeting
Poor Prognosis of Patients with Primary Sjögren Syndrome Who Fulfilled at Diagnosis the Classification Criteria for Concomitant Cryoglobulinemic Vasculitis
Soledad Retamozo^1,2, Hoda Gheitasi³, Luca Quartuccio⁴, Belchin Kostov⁵, Laura Corazza⁴, Albert Bové³, Antoni Sisó-Almirall⁵, Myriam Gandía³, Manuel Ramos-Casals¹, Salvatore De Vita⁶ and Pilar Brito-Zerón¹, ¹Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Department of Autoimmune Diseases, IDIBAPS, Hospital Clínic, Barcelona, Spain, ⁴S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ⁵Primary Care Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain, ⁶Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: To evaluate the fulfilment of classification criteria for cryoglobulinemic vasculitis (CV) at diagnosis in a large cohort of patients with primary Sjögren syndrome (SS)…
Abstract Number: 1052 • 2015 ACR/ARHP Annual Meeting
Identification of Novel Sjogren’s Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1
Christopher J. Lessard^1,2, He Li^1,2, John Ice², Indra Adrianto³, Astrid Rasmussen², Kiely Grundahl⁴, Jennifer A. Kelly⁵, Corinne Miceli⁶, Simon Bowman⁷, Susan Lester⁸, Johan G. Brun^9,10, Lasse G. Goransson¹¹, Erna Harboe¹¹, Joel M. Guthridge², Kenneth M. Kaufman^12,13, Per Eriksson¹⁴, Maija-Leena Eloranta¹⁵, Marika Kvarnström¹⁶, Deborah S. Cunninghame-Graham¹⁷, A. Darise Farris², Michael T. Brennan¹⁸, James Chodosh¹⁹, Raj Gopalakrishnan²⁰, Andrew J.W. Huang²¹, Pamela Hughes²², David M. Lewis²³, Lida Radfar²⁴, Michael D. Rohrer²⁵, Donald U. Stone²⁶, Timothy J. Vyse¹⁷, Patrick M. Gaffney², Judith A. James^1,5,27, John B. Harley^12,28, Roald Omdal¹¹, Marie Wahren-Herlenius¹⁶, Gabor G. Illei²⁹, Torsten Witte³⁰, Roland Jonsson^10,31, Maureen Rischmueller^32,33, Lars Rönnblom³⁴, Xavier Mariette³⁵, Juan-Manuel Anaya³⁶, Wan-Fai Ng³⁷, Gunnel Nordmark³⁴, Courtney G. Montgomery², Nelson L. Rhodus³⁸, Barbara M. Segal³⁹, R. Hal Scofield^2,27,40 and Kathy L. Sivils^1,2, ¹Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, PARIS, France, ⁷Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁸Queen Elizabeth Hospital, Adelaide, Australia, ⁹Institute of Internal Medicine, University of Bergen, Bergen, Norway, ¹⁰Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹²US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, ¹⁵Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁶Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ¹⁸Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ²⁰Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ²¹Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, ²²Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ²³College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ²⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁶Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁸Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁹National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, ³⁰Hannover Medical School, Hanover, Germany, ³¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ³²University of Adelaide, Adelaide, Australia, ³³Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³⁴Rheumatology, Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ³⁵AP-HP, Hopitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, France, ³⁶Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ³⁷Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁸Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ⁴⁰US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors playing important roles in its pathophysiology. The goal of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].